A case report describes AGEP occurrence during pembrolizumab therapy in a lung cancer patient, indicating necessary management adjustments.
We describe a rare case of acute generalised exanthematous pustulosis (AGEP) occurring during pembrolizumab therapy in a patient with metastatic lung adenocarcinoma and longstanding chronic plaque psoriasis. Clinical and histopathological findings confirmed AGEP rather than generalised pustular psoriasis, and cessation of pembrolizumab and treatment with acitretin led to complete resolution. This case highlights the importance of early recognition and multidisciplinary management of immunotherapy-related cutaneous toxicity.
No takes yet. Share an insight, caveat, or question.
Ibude et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: